AI GRAND ROUNDS

Authors: GEMINI(RESIDENT), GROK(ATTENDING), CHATGPT (EXPERT) & ANUPAM SINGH MD(Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

Round 1

User: An 85-year-old woman was brought to the emergency department after losing consciousness. Her daughter reported a sudden onset of sweating, palpitations, and feeling cold before she lost consciousness approximately 45 minutes after finishing dinner. There was no reported chest pain, shortness of breath, or urinary incontinence. She had experienced similar but milder symptoms three times in the previous two weeks, each time recovering without assistance. She also reported headaches over the previous few days and an unintentional weight loss of 2 to 3 kg over the last few months.

Resident:

Hello, Chief Resident here.

This case presents an 85-year-old female with recurrent episodes of autonomic instability (sweating, palpitations, feeling cold) culminating in a syncopal event shortly after a meal. The combination of postprandial timing, constitutional symptoms (weight loss), and new-onset headaches in an elderly patient necessitates a broad differential ranging from metabolic disturbances to occult malignancy or vasculitis.

Key Findings:

  1. Postprandial Syncope: Loss of consciousness occurring 45 minutes after dinner.
  2. Autonomic Prodrome: Sweating, palpitations, and "feeling cold" suggest a sympathetic surge or a hypoglycemic response.
  3. Recurrent Nature: Three similar episodes in the last two weeks.
  4. Constitutional Symptoms: Unintentional weight loss (2-3 kg) over several months.
  5. Neurological Symptom: Recent onset of headaches.
  6. Age: 85 years old (high risk for cardiovascular events and malignancy).

Differential Diagnoses:

  1. Reactive Hypoglycemia (specifically Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome - NIPHS or Insulinoma): (45%)
    The timing (45 minutes post-meal) is highly suggestive of postprandial hypoglycemia. While reactive hypoglycemia is often associated with gastric surgery (dumping syndrome), in an elderly patient with weight loss, we must consider an insulinoma or a paraneoplastic process producing insulin-like growth factors.

  2. Pheochromocytoma: (25%)
    The "classic triad" of palpitations, sweating, and headache, combined with weight loss, is highly suspicious. While syncope is less common than hypertension, orthostatic hypotension or arrhythmias associated with catecholamine surges can cause loss of consciousness.

  3. Giant Cell Arteritis (GCA): (15%)
    In an 85-year-old with new headaches and weight loss, GCA must be ruled out. While it doesn't typically cause syncope, systemic vasculitis can lead to various neurological presentations or be associated with other paraneoplastic phenomena.

  4. Cardiac Arrhythmia (e.g., Sick Sinus Syndrome or Paroxysmal AV Block): (10%)
    Syncope in the elderly is cardiac until proven otherwise. The palpitations could represent a tachy-brady syndrome, though the specific postprandial timing makes this less likely than a metabolic cause.

  5. Postprandial Hypotension: (5%)
    A common cause of syncope in the elderly where blood pressure drops significantly after eating due to splanchnic blood pooling. However, this usually doesn't present with significant weight loss or headaches.

Recommended Prioritised Tests:

  1. Fingerstick Glucose and Formal Plasma Glucose/Insulin/C-peptide: Ideally captured during an episode or via a supervised 72-hour fast (if fasting symptoms occur) or a mixed-meal test to confirm hypoglycemia.
  2. Plasma Free Metanephrines or 24-hour Urinary Fractionated Metanephrines: To screen for pheochromocytoma given the headache, sweating, and palpitations.
  3. Inflammatory Markers (ESR and CRP): To screen for Giant Cell Arteritis or occult inflammatory/malignant processes.
  4. 12-Lead ECG and Cardiac Telemetry/Holter Monitor: To evaluate for conduction disturbances or arrhythmias.
  5. CT Abdomen/Pelvis: To investigate the weight loss and look for pancreatic lesions (insulinoma) or adrenal masses (pheochromocytoma).

Next Steps: I would immediately check her orthostatic vitals and bedside glucose. If she is currently asymptomatic, the postprandial nature of the event is the strongest lead.

Attending:

Hello Attending Consultant here.

Critique of plan:

Refined 6-point recommendations:

  1. Immediate capillary glucose, orthostatic vital signs, ECG, troponin, CBC, electrolytes, HbA1c.
  2. Prioritize 24–48 h ambulatory ECG (or inpatient telemetry) over advanced endocrine testing given age and syncope.
  3. Measure paired plasma glucose, insulin, C-peptide, and proinsulin only during a spontaneous symptomatic episode or formal supervised fast; avoid random testing.
  4. Screen for pheochromocytoma with plasma free metanephrines only if sustained hypertension or paroxysmal hypertensive crises documented.
  5. Order ESR/CRP and consider temporal artery ultrasound if headache is new, temporal, or associated with jaw claudication.
  6. If hypoglycemia confirmed and exogenous causes excluded, proceed to contrast-enhanced CT/MRI pancreas rather than broad abdominopelvic CT for weight loss alone.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

Endogenous hyperinsulinemic hypoglycemia, most likely insulinoma, causing recurrent neuroglycopenic syncope with autonomic prodrome.

Why this is the best fit

The strongest clue is the stereotyped autonomic warning symptoms before LOC: sweating, palpitations, feeling cold. That triad strongly suggests adrenergic response to hypoglycemia. Syncope/LOC then reflects neuroglycopenia. Recurrent episodes over 2 weeks, with spontaneous recovery, also fit intermittent hypoglycemia.

The key pivot is that although the episode occurred 45 minutes after dinner, which might tempt one toward postprandial hypotension or “reactive hypoglycemia,” in an 85-year-old with weight loss, recurrent adrenergic episodes plus LOC should make you think first of documented hypoglycemia until proved otherwise, especially endogenous hyperinsulinism.

Top differentials

  1. Insulinoma / endogenous hyperinsulinemic hypoglycemia
    - Fits: recurrent episodes, adrenergic prodrome, LOC, weight loss can occur from altered eating behavior or malignancy concern; symptoms may occur fasting or postprandially.
    - Against: classic insulinoma is more often fasting-related than clearly postprandial, but postprandial episodes can occur.

  2. Postprandial hypoglycemia not due to insulinoma
    - Includes reactive hypoglycemia, medication-related, or less commonly non-insulinoma pancreatogenous hypoglycemia.
    - Fits: episode after a meal.
    - Against: in an elderly woman without known gastric surgery, this is less compelling; recurrent true syncope is more concerning for a pathologic cause.

  3. Postprandial hypotension
    - Fits: elderly patient, event after dinner, syncope after meals is common in older adults.
    - Against: the adrenergic symptoms are more suggestive of hypoglycemia than hypotension; headaches and weight loss are not explained.

  4. Cardiac arrhythmia
    - Fits: elderly patient with syncope; palpitations may precede LOC.
    - Against: the sweating/cold feeling stereotyped before each episode and recurrent meal association are less typical; still must be excluded because of age/risk.

  5. Pheochromocytoma
    - Fits: headache, palpitations, sweating, weight loss.
    - Against: syncope is not a typical dominant manifestation; meal-triggered episodes are not classic; far less likely than hypoglycemia.

  6. Giant cell arteritis
    - Fits: new headache, weight loss, age.
    - Against: does not explain recurrent autonomic episodes with syncope. Important comorbidity to consider, not the unifying diagnosis.

Why the prior reasoning needed correction

The earlier discussion appropriately noticed hypoglycemia and pheochromocytoma, but the central issue is not just “postprandial syncope.” It is autonomic warning symptoms followed by LOC, which is much more diagnostically specific for hypoglycemia than for vasovagal or hemodynamic postprandial syncope. Also, pheochromocytoma was overemphasized.

Most important next diagnostic move

Document Whipple’s triad during an episode:
1. Symptoms consistent with hypoglycemia
2. Low plasma glucose at that time
3. Resolution with glucose

During the episode, obtain:
- Plasma glucose
- Insulin
- C-peptide
- Proinsulin
- Beta-hydroxybutyrate
- Sulfonylurea/meglitinide screen

If she is currently symptomatic in the ED, this should be done immediately before dextrose, if safely possible.

Most important immediate management move

If glucose is low or she is altered: treat hypoglycemia immediately with IV dextrose, then monitor closely. Given recurrent syncope at age 85, she also still needs:
- ECG
- Telemetry
- Basic syncope evaluation

Practical diagnostic pathway

Teaching pearl

In recurrent “spells” with sweating, palpitations, and confusion/syncope, always think hypoglycemia first and try to capture labs during symptoms; imaging comes only after biochemical confirmation.

Round 2

User: Upon arrival of the emergency medical services, the patient was still unconscious. Her temperature was 36.4°C, blood pressure 135/65 mm Hg, heart rate 78 beats per minute, and respiratory rate 12 breaths per minute. Oxygen saturation was 99% on room air. Her eyes were open, pupils were equal and reactive to light, and cardiovascular and pulmonary examinations were normal. Painful stimuli elicited a withdrawal response, but she had incomprehensible speech and could not follow commands. An electrocardiogram was normal. Her random blood sugar was 40 mg/dL. She was immediately given 100 ml of 10% intravenous glucose and promptly regained consciousness.

Resident:

Hello, Chief Resident here.

The clinical picture has sharpened significantly with the documentation of Whipple’s Triad: symptoms of neuroglycopenia (unconsciousness/incomprehensible speech), a documented low blood sugar (40 mg/dL), and prompt resolution of symptoms upon administration of glucose.

Updated Key Findings:

  1. Confirmed Hypoglycemia: Random blood sugar of 40 mg/dL during the event.
  2. Neuroglycopenia: Loss of consciousness and inability to follow commands, resolving with IV glucose.
  3. Postprandial Timing: The event occurred 45 minutes after dinner, which is atypical for a classic fasting insulinoma but highly suggestive of postprandial hyperinsulinemic hypoglycemia.
  4. Constitutional/Neurological Symptoms: Weight loss and headaches remain concerning for an underlying neoplastic or systemic process.

Probability-Based Diagnoses:

  1. Insulinoma (including Malignant Insulinoma): (60%)
    While classically associated with fasting, a significant minority of insulinomas (up to 10%) can present with postprandial symptoms. Given her age and weight loss, a malignant insulinoma must be considered, as it would explain both the hypoglycemia and the constitutional decline.
    Reasoning: The severity of the hypoglycemia (40 mg/dL) and the recurrent nature are hallmarks of endogenous hyperinsulinism.

  2. Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) / Nesidioblastosis: (15%)
    This condition specifically causes postprandial hyperinsulinemic hypoglycemia due to beta-cell hypertrophy.
    Reasoning: Fits the postprandial timing perfectly, though it is rarer than insulinoma in this age group.

  3. Non-Islet Cell Tumor Hypoglycemia (NICTH): (15%)
    Certain tumors (e.g., mesenchymal tumors, hepatocellular carcinoma) secrete "Big-IGF-2," which mimics insulin action.
    Reasoning: This would explain the profound hypoglycemia and the unintentional weight loss.

  4. Factitious Hypoglycemia or Medication-Induced: (5%)
    Accidental or intentional ingestion of sulfonylureas or insulin.
    Reasoning: Always a possibility in the elderly (e.g., taking a spouse's medication), though less likely to explain the weight loss and headaches.

  5. Adrenal Insufficiency: (5%)
    Glucocorticoid deficiency can lead to hypoglycemia and weight loss.
    Reasoning: Usually presents with hypotension and electrolyte abnormalities (hyponatremia/hyperkalemia), which are absent here.

Recommended Prioritised Tests:

  1. "Critical Sample" during next episode (or supervised provocation): Measure plasma glucose, Insulin, C-peptide, Proinsulin, and Beta-hydroxybutyrate. This is the gold standard to differentiate insulinoma (high insulin/C-peptide) from NICTH (low insulin/C-peptide) or exogenous insulin (high insulin/low C-peptide).
  2. Oral Glucose Tolerance Test (OGTT) or Mixed-Meal Test: To formally reproduce the postprandial hypoglycemia under controlled conditions.
  3. Serum Sulfonylurea/Meglitinide Screen: To rule out occult ingestion of secretagogues.
  4. Triple-Phase CT of the Pancreas: To look for a hypervascular neuroendocrine tumor (insulinoma).
  5. IGF-1 and IGF-2 Levels: If insulin and C-peptide are suppressed during hypoglycemia, to evaluate for NICTH.

Management Note: The patient should be started on frequent, small, low-glycemic-index meals to prevent further drops while the biochemical workup is completed. Given the headaches and weight loss, I would also keep a low threshold for imaging the head and chest/abdomen to look for primary malignancy or metastases.

Attending:

Hello Attending Consultant here.

Critique of plan:

Refined 6-point recommendations:

  1. Retrieve or redraw “critical sample” (plasma glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate, sulfonylurea screen) from the pre-treatment moment or immediately upon any recurrent episode.
  2. Initiate continuous 10% dextrose infusion titrated to maintain euglycemia while diagnostic work-up proceeds; avoid reliance on oral intake alone in an 85-year-old with recurrent syncope.
  3. Perform 72-hour supervised fast only if fasting hypoglycemia is also documented; otherwise prioritize mixed-meal provocation after biochemical confirmation.
  4. Order contrast-enhanced multiphase pancreatic-protocol CT (or MRI) only after endogenous hyperinsulinism is biochemically proven.
  5. Add IGF-2:IGF-1 ratio if insulin/C-peptide are appropriately suppressed during hypoglycemia to evaluate non-islet-cell tumor hypoglycemia.
  6. Obtain basic age-appropriate malignancy screen (chest radiograph, age-appropriate cancer screening review, basic inflammatory markers) to address weight loss and headaches without over-imaging.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

She now has proven hypoglycemic syncope/neuroglycopenia by Whipple’s triad:
- compatible symptoms/signs: unconsciousness, inability to follow commands
- documented low glucose: 40 mg/dL
- prompt reversal with IV glucose

The leading unifying diagnosis is endogenous hyperinsulinemic hypoglycemia, with insulinoma still high on the list, but at this point the more precise statement is:

Recurrent severe hypoglycemia causing neuroglycopenic syncope, most likely due to endogenous hyperinsulinism until proven otherwise.

Why this is the key pivot

The case is no longer primarily “syncope.”
The decisive pivot is that she was still obtunded when EMS arrived and immediately woke up after dextrose. That converts this from a broad syncope differential into a hypoglycemia differential.

Top differentials now

1. Endogenous hyperinsulinemic hypoglycemia, especially insulinoma

Why it fits
- recurrent episodes over weeks
- adrenergic prodrome: sweating, palpitations
- neuroglycopenia: LOC, confusion
- relief with glucose
- weight loss may reflect reduced intake from recurrent spells

Why it may not fit perfectly
- symptoms seem postprandial, whereas classic insulinoma is often fasting-related
But insulinoma can still present with mixed or postprandial episodes.

2. Postprandial hyperinsulinemic hypoglycemia / non-insulinoma pancreatogenous hypoglycemia

Why it fits
- timing about 45 minutes after dinner
- recurrent meal-related episodes
- could produce the same adrenergic and neuroglycopenic manifestations

Why less certain
- much less common, especially without a history suggesting prior gastric surgery or other predisposition
- still requires biochemical proof of inappropriate insulin secretion

3. Sulfonylurea/meglitinide exposure or other medication-related hypoglycemia

Why it fits
- elderly patients can have accidental ingestion, dispensing errors, or access to others’ medications
- causes endogenous insulin secretion pattern
- can be recurrent and severe

Why less likely
- no medication history given yet
- does not explain headaches/weight loss, though those may be unrelated

4. Non-islet cell tumor hypoglycemia (IGF-2 mediated)

Why it fits
- age and weight loss
- can cause recurrent severe hypoglycemia

Why less likely
- adrenergic postprandial pattern is less classic
- would usually show suppressed insulin/C-peptide, so this remains a biochemical branch-point diagnosis

5. Adrenal insufficiency or other critical illness/endocrine deficiency

Why it fits
- can cause hypoglycemia, weight loss

Why less likely
- vitals are stable, no shock pattern, no obvious systemic illness from the stem
- autonomic spells recurring after meals are less typical

6. Cardiac syncope/postprandial hypotension

Why they no longer lead
- normal ECG does not fully exclude arrhythmia, but the event was clearly glucose-responsive
- these do not explain blood glucose of 40 mg/dL with prompt neurologic recovery after dextrose

Most important next diagnostic move

Obtain a critical sample during hypoglycemia—this is the essential next step.

During a spontaneous recurrent episode, before giving glucose if safely possible, send:
- plasma glucose
- insulin
- C-peptide
- proinsulin
- beta-hydroxybutyrate
- sulfonylurea/meglitinide screen

If a pre-treatment sample from EMS/ED is available, retrieve it urgently.

Most important immediate management move

Because she has had recurrent severe hypoglycemia with loss of consciousness, she should be:
- admitted
- placed on frequent glucose monitoring
- maintained on continuous dextrose support if needed
- given regular carbohydrate intake once safe to eat

Do not rely only on “eat small frequent meals” in an 85-year-old with severe recurrent episodes.

What should come after the biochemical result

About the headaches and weight loss

These remain important, but they are not the immediate pivot. They may be:
- related to recurrent hypoglycemia
- a clue to occult malignancy
- a separate process altogether

They should broaden the workup, but not distract from first establishing the mechanism of hypoglycemia.

Teaching pearl

Once Whipple’s triad is demonstrated, the evaluation should pivot from “Why did she faint?” to “Why is she hypoglycemic?”
In recurrent unexplained episodes with sweating and palpitations, always try to capture a critical sample during hypoglycemia before treatment if safely feasible.

Round 3

User: In the emergency department, the patient appeared well and was alert and oriented. Her vital signs remained stable. Her body-mass index was 22. Physical examination showed no skin abnormalities, no nuchal rigidity, and no motor or sensory deficits. Her medical history was significant only for hypertension, for which she was taking triamterene–hydrochlorothiazide. She had no history of diabetes mellitus, never smoked, and did not consume alcohol. She was of Eritrean descent and had emigrated two weeks previously. Family history was negative for cardiovascular, neurologic, or autoimmune diseases.

Resident:

Resident:
Hello, Chief Resident here.

The clinical picture has shifted dramatically with the addition of one critical piece of information: the patient is of Eritrean descent and emigrated only two weeks ago. This, combined with the documented postprandial hyperinsulinemic hypoglycemia, points toward a specific, geographically-linked autoimmune phenomenon.

Updated Key Findings:

  1. Confirmed Whipple’s Triad: Hypoglycemia (40 mg/dL) with neuroglycopenia, resolving with glucose.
  2. Postprandial Pattern: Symptoms occur specifically after meals (45 minutes post-dinner).
  3. Recent Migration: Emigrated from Eritrea two weeks ago.
  4. Medication: Taking triamterene–hydrochlorothiazide (contains a sulfhydryl-like group or can be associated with idiosyncratic reactions).
  5. Constitutional Symptoms: Weight loss and headaches.

Probability-Based Diagnoses:

  1. Insulin Autoimmune Syndrome (Hirata Disease): (70%)
    This is the leading diagnosis. It is characterized by high titers of insulin autoantibodies that bind insulin after a meal (leading to early hyperglycemia) and then dissociate unpredictably, causing massive, inappropriate late postprandial hypoglycemia.
    Reasoning: While most common in Japanese populations, it is the second most common cause of endogenous hyperinsulinemic hypoglycemia in some other groups. Certain medications (especially those with sulfhydryl groups like methimazole, but occasionally others) can trigger it. The "feeling cold" and sweating are classic adrenergic responses to the sudden insulin surge as antibodies release their load.

  2. Insulinoma: (15%)
    Still a possibility in any elderly patient with endogenous hyperinsulinism, but the strictly postprandial nature and the new demographic information make Hirata disease more likely.
    Reasoning: Weight loss could be seen in malignant insulinoma, but the timing is more classic for IAS.

  3. Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): (10%)
    Postprandial hyperinsulinism due to beta-cell hypertrophy.
    Reasoning: Fits the timing, but less likely to explain the sudden onset over two weeks and the constitutional symptoms.

  4. Factitious Hypoglycemia: (5%)
    Reasoning: Less likely given the recent migration and lack of access to insulin/secretagogues, but must always be ruled out by C-peptide and drug screens.

Recommended Prioritised Tests:

  1. Insulin Autoantibody (IAA) Titer: This is the definitive test for Hirata Disease. Expect extremely high levels.
  2. Total vs. Free Insulin Levels: In Hirata Disease, total insulin is often "sky-high" (often >1000 μU/mL) because the assay measures antibody-bound insulin, while free insulin is what causes the symptoms.
  3. C-peptide and Proinsulin: These will be elevated during the episode (as the body is secreting insulin normally in response to the meal), but the insulin-to-C-peptide ratio is often characteristically high in IAS.
  4. Sulfonylurea/Meglitinide Screen: To rule out exogenous secretagogues.
  5. Imaging (CT Pancreas): To rule out insulinoma if antibodies are negative, though I would wait for the IAA results first.

Management Reasoning:

The headaches and weight loss might be secondary to the metabolic stress of recurrent severe hypoglycemia or could suggest an underlying systemic autoimmune process. If Hirata Disease is confirmed, management involves small, frequent, low-carbohydrate meals and occasionally corticosteroids or immunosuppressants.

Chief Resident's Conclusion: The recent migration and postprandial timing are the "smoking guns" for Insulin Autoimmune Syndrome. I suspect her insulin levels will be paradoxically and massively elevated.

Attending:

Hello Attending Consultant here.

Critique of plan:

Refined 6-point recommendations:

  1. Immediately retrieve or redraw critical sample (glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate, oral hypoglycemic screen) from the hypoglycemic episode; measure insulin autoantibodies (IAA) and anti-insulin receptor antibodies concurrently.
  2. Discontinue triamterene–hydrochlorothiazide and substitute with non-sulfhydryl antihypertensive to remove potential trigger.
  3. Initiate continuous dextrose infusion or frequent low-glycemic-index feeds with close q1–2h glucose monitoring until biochemical mechanism is clarified.
  4. Perform thick/thin malaria smears and chest radiograph given recent Eritrean emigration, weight loss, and headaches; add ESR/CRP and consider QuantiFERON-TB.
  5. If IAA markedly elevated with disproportionately high total insulin, confirm IAS and trial dietary modification ± short-course glucocorticoids; reserve pancreatic-protocol CT/MRI for IAA-negative cases only.
  6. Obtain basic nutritional markers (prealbumin, B12, folate) and age-appropriate malignancy screen to explain unintentional weight loss without premature advanced imaging.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

Insulin autoimmune syndrome (IAS, Hirata disease) causing recurrent postprandial hyperinsulinemic hypoglycemia.

Why this now rises to the top

The new details shift the case away from insulinoma as the default:

IAS is particularly attractive because it often presents with:
- postprandial hypoglycemia
- very high insulin levels
- spontaneous recurrent episodes
- absence of pancreatic tumor

Top differentials, with fit vs mismatch

1. Insulin autoimmune syndrome

Fits
- postprandial pattern
- recurrent severe hypoglycemia
- no diabetes
- spontaneous recovery between episodes
- possible drug trigger
- can occur in older adults and may be missed if clinicians focus only on insulinoma

Against
- relatively uncommon
- weight loss/headaches are not classic defining features

2. Insulinoma

Fits
- endogenous hyperinsulinemic hypoglycemia can certainly cause this presentation
- recurrent severe episodes with neuroglycopenia

Against
- insulinoma more often causes fasting hypoglycemia, though not exclusively
- the repeated post-meal timing makes IAS more compelling right now

3. Sulfonylurea/meglitinide exposure

Fits
- can mimic endogenous hyperinsulinism
- severe recurrent episodes possible in older adults

Against
- no diabetes history, no such medication reported
- still must be ruled out biochemically

4. Non-insulinoma pancreatogenous hypoglycemia / nesidioblastosis

Fits
- postprandial hyperinsulinemia

Against
- rarer and usually a diagnosis after more common explanations are excluded

5. Non-islet cell tumor hypoglycemia

Fits
- weight loss

Against
- would usually show suppressed insulin/C-peptide, so less likely given the clinical pattern suggesting hyperinsulinism

Key pivot in the case

The most important pivot is not simply that she is hypoglycemic, but that her episodes are reproducibly postprandial in a nondiabetic patient, which is a classic clue for IAS rather than classic insulinoma.

Most important next diagnostic move

Obtain or retrieve a critical hypoglycemia sample, specifically:
- plasma glucose
- insulin
- C-peptide
- proinsulin
- beta-hydroxybutyrate
- sulfonylurea/meglitinide screen

And now, crucially:
- insulin autoantibodies

If available, try to recover any pre-dextrose blood from the ED/EMS encounter.

Most important management move

If IAS is confirmed and symptoms are significant, treatment may include:
- dietary modification
- short-course glucocorticoids
- rarely other immunomodulatory therapies

One teaching pearl

In a nondiabetic patient with recurrent postprandial hypoglycemia, especially if insulin levels later prove strikingly high, think insulin autoimmune syndrome before chasing a pancreatic tumor.

Round 4

User: Initial laboratory investigations showed a complete blood count within the normal range, with a normal Total Leukocyte Count (TLC). The plasma glucose level was 176.4 mg/dL and the glycated hemoglobin (HbA1c) was 5.5%. Kidney Function Tests (KFT) showed a sodium level of 130 mmol/L, potassium 3.7 mmol/L, and creatinine 0.51 mg/dL. Liver Function Tests (LFT) including AST, ALT, alkaline phosphatase, γ-glutamyltransferase, and total bilirubin were all normal. Calcium was 9.1 mg/dL, C-reactive protein was 3 mg/L (normal <8), and TSH was normal. The patient was admitted for further evaluation.

Resident:

Resident:
Hello, Chief Resident here.

The initial laboratory results provide several important negative findings that help narrow our focus, while also introducing a mild electrolyte abnormality.

Updated Key Findings:

  1. Normal Inflammatory Markers: CRP is normal (3 mg/L), which significantly reduces the likelihood of Giant Cell Arteritis or a major systemic inflammatory process as the cause of her headaches and weight loss.
  2. Normal HbA1c (5.5%): Confirms she does not have pre-existing diabetes or chronic hyperglycemia, making the hypoglycemia even more significant.
  3. Mild Hyponatremia (130 mmol/L): This could be due to the hydrochlorothiazide she was taking, or it could be a subtle hint toward adrenal insufficiency (though potassium is normal).
  4. Normal LFTs and KFTs: Rules out hepatic or renal failure as a cause for hypoglycemia.
  5. Normal TLC: Reduces the likelihood of an acute occult infection.

Probability-Based Diagnoses:

  1. Insulin Autoimmune Syndrome (IAS / Hirata Disease): (75%)
    The postprandial timing remains the strongest clinical lead. The normal CRP and TLC make a primary inflammatory or infectious cause for her constitutional symptoms less likely, supporting the idea that the "spells" themselves or a specific autoimmune process are the primary drivers.
    Reasoning: The demographic and clinical pattern (postprandial hypoglycemia in a non-diabetic) is classic for IAS.

  2. Insulinoma: (15%)
    Remains a possibility. While insulinomas often cause fasting hypoglycemia, they can present postprandially. The weight loss still keeps this on the radar.
    Reasoning: Endogenous hyperinsulinism is confirmed by the glucose response; the source (antibody vs. tumor) is the next question.

  3. Adrenal Insufficiency (Primary or Secondary): (5%)
    The hyponatremia (130 mmol/L) and weight loss could be explained by glucocorticoid deficiency.
    Reasoning: Hypoglycemia is a known manifestation, though the postprandial autonomic surges are less typical than for IAS.

  4. Non-Islet Cell Tumor Hypoglycemia (NICTH): (5%)
    Reasoning: Still possible given the weight loss, though the postprandial timing is less common than in IAS.

Recommended Prioritised Tests:

  1. Insulin Autoantibodies (IAA): This is the highest yield test to confirm IAS.
  2. Critical Sample Analysis (from the 40 mg/dL event or a repeat): We urgently need the Insulin, C-peptide, and Proinsulin levels from the time of hypoglycemia. In IAS, the insulin level is typically disproportionately high (often >1000 μU/mL) compared to the C-peptide.
  3. Morning Cortisol and ACTH: To investigate the hyponatremia and weight loss and rule out adrenal insufficiency.
  4. Sulfonylurea Screen: To rule out occult ingestion.
  5. Imaging (CT Abdomen/Pancreas): Only after biochemical confirmation of the type of hyperinsulinism.

Management Note: I would discontinue the triamterene-hydrochlorothiazide immediately, both to address the hyponatremia and because thiazides/sulfonamide-derivatives are potential triggers for IAS. I would also monitor her blood pressure closely and start a low-simple-carbohydrate diet with frequent small meals.

Chief Resident's Conclusion: The normal CRP pushes us further away from vasculitis and toward a primary metabolic/autoimmune insulin disorder. The hyponatremia is likely diuretic-induced but warrants a quick check of adrenal function. The focus remains on confirming Insulin Autoimmune Syndrome.

Attending:

Hello Attending Consultant here.

Critique of plan:

Refined 6-point recommendations:

  1. Retrieve or redraw critical sample (glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate, sulfonylurea screen) from the index hypoglycemic episode before any further glucose load.
  2. Order insulin autoantibody titer and anti-insulin-receptor antibody immediately; interpret only in context of simultaneous critical-sample results.
  3. Discontinue triamterene–hydrochlorothiazide, replace with non-sulfhydryl agent, and evaluate hyponatremia with paired serum/urine osmolality, urine sodium, morning cortisol, and ACTH.
  4. Maintain euglycemia with continuous 5–10% dextrose infusion plus frequent low-glycemic-index feeds; avoid reliance on oral intake alone until mechanism clarified.
  5. Perform malaria smear, chest radiograph, and QuantiFERON-TB given Eritrean origin, weight loss, and headaches; defer pancreatic-protocol CT/MRI until biochemical confirmation of endogenous hyperinsulinism.
  6. If IAA positive with disproportionately elevated total insulin, confirm IAS and trial dietary modification ± glucocorticoids; if negative, proceed to 72-hour fast or mixed-meal test with imaging.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

Still most likely: recurrent hypoglycemia due to endogenous hyperinsulinemia, with insulin autoimmune syndrome (IAS) currently favored.

Why these new labs matter

They mostly help by excluding common systemic causes of hypoglycemia:

These results do not distinguish IAS from insulinoma; that requires critical-sample biochemistry during hypoglycemia.

Top differentials now

1. Insulin autoimmune syndrome

Why it fits
- repeated postprandial hypoglycemia
- nondiabetic patient
- otherwise well between episodes
- possible medication trigger
- no evidence yet of organ failure or critical illness

Why not proven yet
- needs insulin autoantibodies
- must still exclude sulfonylurea exposure and insulinoma biochemically

2. Insulinoma

Why it fits
- Whipple’s triad
- recurrent severe neuroglycopenic episodes

Why slightly less favored
- pattern seems more postprandial than fasting

3. Sulfonylurea/meglitinide-related hypoglycemia

Why it fits
- can present exactly like endogenous hyperinsulinism
- elderly patients are vulnerable to medication mix-ups

Why less favored
- no known diabetes meds, but still must be tested

4. Adrenal insufficiency

Why it fits
- weight loss, hyponatremia, hypoglycemia can occur

Why less favored
- normal potassium, stable hemodynamics, and strongly meal-related episodes argue against it as the main explanation

Key pivot in the case

The pivot remains: this is not unexplained syncope; it is documented hypoglycemic neuroglycopenia.
The newer pivot is that routine labs are largely normal, making a specific hyperinsulinemic disorder more likely.

Most important next diagnostic move

Get the mechanism of hypoglycemia now.
Highest-yield tests:

During spontaneous hypoglycemia, obtain:
- plasma glucose
- insulin
- C-peptide
- proinsulin
- beta-hydroxybutyrate
- sulfonylurea/meglitinide screen

Also send:
- insulin autoantibodies

If no pre-dextrose sample exists from the original event, the patient should be monitored closely to capture one safely if hypoglycemia recurs.

Most important next management move

Additional but secondary workup

Because of weight loss + headache + recent emigration, I would also consider:
- morning cortisol
- serum/urine osmolality and urine sodium for hyponatremia
- targeted infectious screening if clinically indicated (e.g., TB/malaria based on exposure/symptoms)

But these are secondary to establishing the biochemical cause of the hypoglycemia.

Teaching pearl

Normal routine labs do not reassure you in severe recurrent hypoglycemia; they should instead push you toward a focused “critical sample” strategy to identify endogenous hyperinsulinism, drug effect, or autoimmune insulin binding.

Round 5

User: Five hours after admission, the patient's blood sugar decreased to 35 mg/dL despite adequate food intake. She was sweating profusely and felt very weak but remained conscious. The glucose level was restored with 120 ml of 40% glucose infusion. Within an hour, her blood sugar was 193 mg/dL. A continuous infusion of 5% glucose was started, but hypoglycemia recurred. The concentration was increased to 20% glucose at 2000 ml per 24 hours. A low-dose corticotropin stimulation test showed a cortisol increase from 10.8 to 23.7 µg/dL after 30 minutes, ruling out hypocortisolism.

Resident:

Resident:
Hello, Chief Resident here.

The case has reached a critical juncture. We now have a recurrent, severe hypoglycemic event (35 mg/dL) occurring despite oral intake and requiring high-concentration IV dextrose (20% glucose) to maintain euglycemia. This confirms a state of profound, persistent endogenous hyperinsulinism.

Updated Key Findings:

  1. Refractory Hypoglycemia: Recurrence of severe hypoglycemia (35 mg/dL) despite food and 5% dextrose, requiring 20% dextrose infusion.
  2. Adrenal Insufficiency Ruled Out: Normal response to corticotropin stimulation (peak cortisol >18 µg/dL) excludes hypocortisolism as the cause.
  3. Autonomic Symptoms: Profuse sweating and weakness during the 35 mg/dL event confirm the adrenergic surge.
  4. Rebound Hyperglycemia: Glucose rose to 193 mg/dL after treatment, which is common but can also be seen in IAS as the "unbound" insulin is cleared and the dextrose takes effect.

Probability-Based Diagnoses:

  1. Insulin Autoimmune Syndrome (IAS / Hirata Disease): (80%)
    The severity and the "brittle" nature of the glucose levels (crashing despite intake, then requiring massive dextrose) are very characteristic of IAS. In IAS, the antibodies act as a reservoir, releasing massive amounts of insulin unpredictably.
    Reasoning: The postprandial trigger and the demographic context remain the strongest drivers.

  2. Insulinoma: (15%)
    A high-secreting insulinoma can certainly require 20% dextrose.
    Reasoning: While the timing was initially postprandial, she is now having "fasting" or "inter-meal" hypoglycemia while admitted, which is the classic presentation of insulinoma.

  3. Non-Islet Cell Tumor Hypoglycemia (NICTH): (3%)
    Reasoning: Less likely given the autonomic symptoms (NICTH often has fewer adrenergic symptoms than hyperinsulinemic states) and the normal cortisol.

  4. Factitious Hypoglycemia: (2%)
    Reasoning: Extremely unlikely in a supervised hospital setting with a 20% dextrose requirement, but a sulfonylurea screen is still mandatory.

Recommended Prioritised Tests:

  1. Critical Sample Results (Urgently): We must see the Insulin, C-peptide, and Proinsulin from the 35 mg/dL event.
    • IAS Pattern: Extremely high Insulin (often >1000), moderately high C-peptide.
    • Insulinoma Pattern: High Insulin, high C-peptide, high Proinsulin.
  2. Insulin Autoantibodies (IAA): This will be the "smoking gun" for IAS.
  3. Sulfonylurea/Meglitinide Screen: To formally exclude secretagogues.
  4. Imaging (CT Pancreas - Triple Phase): If the critical sample confirms endogenous hyperinsulinism and IAA is negative, we must look for a tumor.
  5. IGF-1/IGF-2 Ratio: Only if insulin/C-peptide are suppressed.

Management Reasoning:

The patient is currently on a high-dose glucose "rollercoaster."
* Immediate Action: If IAS is suspected, Acarbose can sometimes help by slowing carbohydrate absorption and reducing the initial insulin surge that "loads" the antibodies.
* Steroids: If IAS is confirmed, starting Prednisone (e.g., 40–60 mg) often results in rapid stabilization of glucose levels by decreasing antibody production and affinity.
* Octreotide: Could be considered if an insulinoma is suspected, though it can occasionally worsen hypoglycemia in IAS or certain insulinomas.

Chief Resident's Conclusion: We have confirmed a state of severe endogenous hyperinsulinism. Given the demographic and the postprandial onset, Insulin Autoimmune Syndrome is the most likely culprit. We are awaiting the "critical sample" and antibody titers to confirm.

Attending:

Hello Attending Consultant here.

Critique of plan:

Refined 6-point recommendations:

  1. Analyze critical sample from the 35 mg/dL episode (insulin, C-peptide, proinsulin, β-hydroxybutyrate, sulfonylurea screen) and order insulin autoantibody titer on the same draw.
  2. Reduce glucose infusion to 10–15% via central line titrated to euglycemia (target 70–90 mg/dL) while calculating total carbohydrate load to avoid fluid overload.
  3. Discontinue hydrochlorothiazide permanently and recheck serum osmolality/urine sodium to resolve hyponatremia.
  4. If IAA markedly positive with disproportionately high total insulin, confirm IAS and initiate prednisone 0.5–1 mg/kg after dietary optimization; reserve octreotide for biochemically proven insulinoma.
  5. Screen for occult infection (malaria smear, chest radiograph, interferon-gamma release assay) given emigration history and weight loss before escalating steroids.
  6. If IAA negative and endogenous hyperinsulinism confirmed, proceed directly to multiphase pancreatic CT or EUS; defer acarbose until mechanism clarified.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

The best current diagnosis is still endogenous hyperinsulinemic hypoglycemia, and at this stage insulin autoimmune syndrome (IAS) remains the leading specific cause.

Why this is now even more convincing

New features strongly support a persistent insulin-mediated process:

This is not simple starvation, adrenal failure, liver disease, renal failure, or sepsis. The physiology now points strongly toward inappropriate insulin effect.

Top differentials now

1. Insulin autoimmune syndrome

Why it fits well
- often causes postprandial hypoglycemia
- can produce marked glycemic volatility with recurrent drops despite feeding
- can require large glucose loads because insulin bound to antibodies is released unpredictably
- no diabetes history
- possible medication trigger
- normal cortisol response removes a major endocrine mimic

Why not yet proven
- must show insulin autoantibodies
- needs critical-sample pattern consistent with insulin-mediated hypoglycemia

2. Insulinoma

Why it still fits
- now she is also having hypoglycemia outside the immediate meal window
- severe recurrent episodes despite feeding are compatible with insulinoma
- endogenous hyperinsulinism remains a major possibility

Why slightly less favored
- the presentation started with a strongly postprandial pattern, which is a bit less classic for insulinoma

3. Sulfonylurea/meglitinide exposure

Why it fits
- can cause persistent recurrent hypoglycemia despite feeding
- can look exactly like endogenous hyperinsulinism

Why less likely
- no history suggesting access/use, but it still must be excluded with testing, not assumption

4. Non-islet cell tumor hypoglycemia

Why it fits
- weight loss raises the possibility

Why it is less likely now
- usually does not behave like this with clear adrenergic hyperinsulinemic-type spells
- would not be the first explanation for this pattern unless insulin/C-peptide are suppressed

Key pivot in the case

The key pivot now is:

Hypoglycemia is recurring despite oral intake and continuous dextrose, while adrenal insufficiency has been excluded.

That means this is almost certainly a pathologic glucose-lowering process, most likely insulin-mediated.

Most important next diagnostic move

If not already done, the single most important next step is to obtain and urgently process a critical sample from the 35 mg/dL episode:

At this point, because she has had recurrent observed hypoglycemia in the hospital, there is a major missed opportunity if a critical sample was not drawn during the latest event.

Most important management move

She needs safe stabilization while preventing recurrent neuroglycopenia:

What result pattern would clarify the diagnosis?

IAS or endogenous insulin effect:

Exogenous insulin:

Sulfonylurea:

Non-islet cell tumor hypoglycemia:

Teaching pearl

When hypoglycemia persists despite feeding and adrenal insufficiency is excluded, think “inappropriate insulin action” and capture a critical sample immediately—before reflexively escalating imaging or empiric therapy.

Round 6

User: The patient had another hypoglycemic episode with a blood sugar of 16.2 mg/dL accompanied by loss of consciousness. Concomitant laboratory testing showed an extremely high insulin level of 182 µU/mL and a C-peptide level of 2.0 ng/mL. A screening test for sulfonylureas was negative. Computed tomography (CT) of the abdomen showed no pancreatic mass or other intraabdominal abnormalities, but incidentally identified a suspicious lesion in the left breast. Subsequent magnetic resonance imaging (MRI) of the abdomen and endoscopic ultrasonography of the pancreas also showed no abnormalities.

Resident:

Resident:
Hello, Chief Resident here.

We have now reached the biochemical confirmation of endogenous hyperinsulinemic hypoglycemia. The patient experienced a life-threatening glucose level of 16.2 mg/dL with loss of consciousness, and the "critical sample" results are the key to the final diagnosis.

Updated Key Findings:

  1. Profound Hypoglycemia: 16.2 mg/dL with neuroglycopenia.
  2. Inappropriate Insulin Secretion: Insulin is massively elevated at 182 µU/mL (normal during hypoglycemia is <3 µU/mL).
  3. C-peptide Level: 2.0 ng/mL. While this is technically within the "normal" fasting range (0.8–3.1 ng/mL), it is inappropriately non-suppressed for a blood sugar of 16.2 mg/dL (should be <0.6 ng/mL).
  4. Negative Imaging: CT, MRI, and the highly sensitive Endoscopic Ultrasound (EUS) failed to find a pancreatic lesion, making a typical insulinoma much less likely.
  5. Incidental Finding: A suspicious lesion in the left breast.
  6. Negative Drug Screen: Sulfonylureas ruled out.

Probability-Based Diagnoses:

  1. Insulin Autoimmune Syndrome (IAS / Hirata Disease): (90%)
    The biochemical pattern is the "smoking gun." In IAS, the insulin level is often disproportionately higher than the C-peptide level. An insulin-to-C-peptide ratio (in molar terms) >1 is highly suggestive of IAS.
    Reasoning: The combination of extremely high insulin, mildly elevated C-peptide, postprandial onset, and negative pancreatic imaging in an elderly patient (especially with recent migration and thiazide use) is classic for IAS. The antibodies bind insulin, prolonging its half-life and interfering with the assay, leading to these "sky-high" values.

  2. Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): (5%)
    Reasoning: This causes postprandial hyperinsulinism with negative imaging, but the insulin levels are rarely this extreme.

  3. Malignant Insulinoma (Occult): (3%)
    Reasoning: While EUS is excellent, a very small or ectopic insulinoma could be missed, but the biochemical ratio favors IAS.

  4. Paraneoplastic Hypoglycemia (related to the breast lesion): (2%)
    Reasoning: If the breast lesion is malignant, it could theoretically cause NICTH, but that would typically present with low insulin and low C-peptide. However, rare cases of ectopic insulin secretion by non-pancreatic tumors exist.

Recommended Prioritised Tests:

  1. Insulin Autoantibodies (IAA): This is now the mandatory confirmatory test. A very high titer will confirm IAS.
  2. Biopsy of the Breast Lesion: Given the weight loss, headaches, and suspicious imaging, we must rule out malignancy. This may be the primary driver of her constitutional symptoms, even if the hypoglycemia is a separate autoimmune phenomenon (IAS).
  3. Free vs. Total Insulin: If the lab can perform it, measuring free insulin (the biologically active fraction) vs. total insulin (antibody-bound) would further support IAS.

Management Reasoning:

The patient is at high risk for further life-threatening drops.
* Immediate: Start Prednisone (e.g., 40–60 mg daily). Corticosteroids are the treatment of choice for IAS as they decrease antibody production and decrease the affinity of the antibodies for insulin, stabilizing the "reservoir" effect.
* Diet: Strict low-carbohydrate, frequent small meals to minimize the postprandial insulin surge that "charges" the antibody reservoir.
* Breast Workup: Urgent mammography and biopsy.

Chief Resident's Conclusion: The biochemical data (massive insulin, non-suppressed C-peptide) and negative pancreatic imaging strongly point to Insulin Autoimmune Syndrome. The suspicious breast lesion must be investigated as a potential malignancy that could be related (paraneoplastic) or a significant co-morbidity.

Attending:

Hello Attending Consultant here.

Critique of plan:

Refined 6-point recommendations:

  1. Calculate molar insulin-to-C-peptide ratio on the 16.2 mg/dL sample and order insulin autoantibody titer plus anti-insulin-receptor antibodies immediately.
  2. Perform urgent core biopsy and mammography of the left-breast lesion while obtaining IGF-2:IGF-1 ratio and β-hydroxybutyrate to exclude NICTH or ectopic insulin secretion.
  3. Initiate prednisone (0.5 mg/kg) only after IAA confirmation and negative infection screen (malaria smear, chest radiograph, QuantiFERON-TB); continue titrated 10–15% dextrose via central line targeting glucose 70–90 mg/dL.
  4. Implement strict low-glycemic-index frequent feeding protocol and discontinue all thiazide diuretics to remove potential IAS trigger.
  5. If IAA positive, monitor for spontaneous remission over 3–6 months; if negative, consider selective arterial calcium stimulation testing despite negative EUS.
  6. Reassess total parenteral glucose load daily to prevent fluid overload and refeeding syndrome in this malnourished elderly patient.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

Insulin autoimmune syndrome (IAS, Hirata disease) causing endogenous hyperinsulinemic hypoglycemia.

Why this is now the best diagnosis

At glucose 16.2 mg/dL, she had:
- Insulin 182 µU/mL: profoundly inappropriately elevated
- C-peptide 2.0 ng/mL: inappropriately non-suppressed
- Negative sulfonylurea screen
- No pancreatic lesion on CT, MRI, or EUS

That combination strongly argues for endogenous insulin effect without a localizable insulinoma, and the earlier postprandial pattern points especially toward IAS.

A practical discriminator here is the disproportionately high insulin relative to C-peptide, which is classic in IAS because insulin autoantibodies prolong insulin half-life and distort measured total insulin upward.

Why the main alternatives fit less well

1. Insulinoma

Fits: endogenous hyperinsulinemic hypoglycemia
Does not fit as well: triple-negative localization workup so far:
- pancreatic CT negative
- MRI negative
- EUS negative

A tiny occult insulinoma is still possible, but it is now less likely than IAS.

2. Sulfonylurea-related hypoglycemia

Fits: can produce high insulin and C-peptide
Against: screen negative

3. Non-insulinoma pancreatogenous hypoglycemia / nesidioblastosis

Fits: postprandial hypoglycemia, negative imaging
Against: less common, and the markedly elevated insulin level with this overall phenotype still favors IAS

4. Non-islet cell tumor hypoglycemia

Against strongly: would usually show suppressed insulin and C-peptide, which she does not

5. Breast lesion causing ectopic insulin secretion

This is extraordinarily rare. The breast lesion is important, but it is not the best explanation for the current biochemical pattern.

Key pivot in the case

The key pivot is:

Severe hypoglycemia with markedly elevated insulin, non-suppressed C-peptide, negative sulfonylurea screen, and negative pancreatic imaging.

That is the classic moment to think:
- insulin autoimmune syndrome
- then only secondarily occult insulinoma/nesidioblastosis

Most important next diagnostic move

Order insulin autoantibodies now if not already sent.
This is the most important confirmatory test.

Helpful adjuncts:
- repeat critical-sample interpretation if needed
- beta-hydroxybutyrate if not already measured
- consider free vs total insulin if available

If insulin autoantibodies are positive, that would strongly confirm IAS.

Most important management move

Given recurrent life-threatening hypoglycemia:
- continue careful dextrose support
- frequent low-carbohydrate / low-glycemic meals
- stop potential triggering medications, especially triamterene–hydrochlorothiazide
- if hypoglycemia remains difficult to control, glucocorticoid therapy is reasonable, especially once IAS is strongly supported/confirmed

What to do about the breast lesion

It needs standard oncologic evaluation:
- diagnostic mammography
- targeted ultrasound
- core biopsy

But it is probably a parallel finding, not the primary explanation for the hyperinsulinemic hypoglycemia.

Teaching pearl

When hypoglycemia occurs with very high insulin, detectable C-peptide, negative sulfonylurea screen, and no pancreatic lesion, think insulin autoimmune syndrome—especially if the episodes are postprandial.

Round 7

User: Treatment with subcutaneous octreotide injections was started, and the patient's glucose levels stabilized. Testing for insulin antibodies returned strongly positive at a titer of more than 50 U/L (reference range 0 to 0.4). This confirmed a diagnosis of Insulin Autoimmune Syndrome (Hirata disease). Further evaluation of the breast lesion via biopsy revealed invasive ductal carcinoma.

Resident:

Resident:
Hello, Chief Resident here.

The case has reached a definitive conclusion with the biochemical confirmation of Insulin Autoimmune Syndrome (IAS/Hirata Disease) and the simultaneous discovery of Invasive Ductal Carcinoma of the breast.

Final Key Findings:

  1. Confirmed IAS: Insulin autoantibody titer >50 U/L (extremely high) confirms the diagnosis. This explains the postprandial hypoglycemia, the "sky-high" insulin levels, and the negative pancreatic imaging.
  2. Malignancy: Biopsy of the incidental breast lesion confirmed invasive ductal carcinoma. This likely explains the patient's unintentional weight loss and potentially the headaches (via systemic effects or stress).
  3. Treatment Response: Stabilization with octreotide is noted, although the mainstay for IAS is typically dietary modification and glucocorticoids.

Final Probability-Based Diagnoses:

  1. Insulin Autoimmune Syndrome (Hirata Disease): (100%)
    Reasoning: Confirmed by high-titer insulin autoantibodies, inappropriate hyperinsulinemia during hypoglycemia, and negative pancreatic imaging.
  2. Invasive Ductal Carcinoma of the Breast: (Confirmed)
    Reasoning: Confirmed by biopsy.

Analysis of the Unifying Picture:

While IAS is often triggered by medications (like the thiazide this patient was taking), there is a known association between IAS and other autoimmune or neoplastic processes. In this case, the breast cancer may have acted as a systemic trigger for the immune dysregulation leading to IAS, or they may be two independent conditions occurring in an 85-year-old patient.

Management and Next Steps:

  1. Hypoglycemia Management:

    • Dietary: Continue small, frequent, low-glycemic-index meals to prevent the postprandial insulin surge that "loads" the autoantibodies.
    • Pharmacotherapy: While octreotide was used here, Prednisone is often the gold standard to reduce antibody titers and affinity. Acarbose can also be used to slow carbohydrate absorption.
    • Monitoring: Most cases of IAS are self-limiting (remitting within 3–6 months) once the trigger (e.g., thiazide) is removed.
  2. Oncological Management:

    • Referral to Surgical Oncology and Medical Oncology for staging and treatment of the invasive ductal carcinoma. Given her age (85), treatment will need to be tailored to her functional status and goals of care.
  3. Follow-up:

    • Serial monitoring of insulin autoantibody titers and blood glucose.
    • Resolution of hyponatremia now that the thiazide has been discontinued.

Final Teaching Pearl:
In an elderly patient with "spells" and weight loss, always look for both the metabolic explanation (hypoglycemia) and the systemic one (malignancy). Insulin Autoimmune Syndrome should be suspected whenever there is severe hyperinsulinemia that does not match the C-peptide level or imaging, especially if symptoms are postprandial. The recent migration and medication use were the crucial clues in this complex presentation.

Attending:

Hello Attending Consultant here.

Critique of resident plan:

Refined 6-point recommendations:

  1. Calculate and report molar insulin-to-C-peptide ratio on all critical samples; add β-hydroxybutyrate and IGF-2:IGF-1 to exclude occult NICTH from breast carcinoma.
  2. Discontinue octreotide if solely IAS-driven; initiate prednisone 0.5–1 mg/kg with rapid taper guided by serial IAA titers and glucose stability.
  3. Stage breast carcinoma fully (ER/PR/HER2, axillary ultrasound, bone scan or PET-CT as indicated) before deciding surgery vs systemic therapy given age and frailty.
  4. Complete infection screen (malaria smear, chest radiograph, QuantiFERON-TB) prior to steroids in recent Eritrean immigrant with constitutional symptoms.
  5. Maintain low-glycemic frequent feeding, discontinue all thiazides permanently, and monitor for spontaneous IAS remission over 3–6 months.
  6. Convene multidisciplinary meeting (endocrinology, oncology, geriatrics) for goals-of-care discussion, nutritional support, and hypoglycemia safety plan before discharge.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis

Confirmed Insulin Autoimmune Syndrome (IAS, Hirata disease) causing recurrent severe endogenous hyperinsulinemic hypoglycemia, with concurrent invasive ductal breast carcinoma.

Why this diagnosis is secure

IAS is now definitively established by:
- documented Whipple’s triad
- profound hypoglycemia with inappropriately high insulin
- non-suppressed C-peptide
- negative sulfonylurea screen
- no pancreatic lesion on CT, MRI, or EUS
- strongly positive insulin antibodies (>50 U/L; ref 0–0.4)

That is the decisive biochemical and clinical pattern.

Top differentials and why they now fall away

  1. Insulinoma
    - Initially plausible due to endogenous hyperinsulinemic hypoglycemia.
    - Now much less likely because pancreatic CT, MRI, and EUS were negative and insulin antibodies are strongly positive, which directly explains the syndrome.

  2. Sulfonylurea-induced hypoglycemia
    - Mimics endogenous hyperinsulinism.
    - Excluded by the negative sulfonylurea screen.

  3. Non-islet cell tumor hypoglycemia
    - Considered because of weight loss and malignancy.
    - Does not fit because this usually causes low insulin and low C-peptide, whereas this patient had marked hyperinsulinemia.

  4. Adrenal insufficiency
    - Mild hyponatremia and weight loss made it worth checking.
    - Appropriately excluded by a normal corticotropin stimulation test.

Key pivot in the case

The pivotal moment was the critical sample during profound hypoglycemia showing:
- glucose 16.2 mg/dL
- insulin 182 µU/mL
- C-peptide 2.0 ng/mL
- negative sulfonylurea screen

That established endogenous insulin-mediated hypoglycemia.
The second pivot was the strongly positive insulin antibody titer, which converted suspicion into confirmation of IAS.

How the breast cancer fits

The breast lesion explains the constitutional symptoms, especially weight loss, and possibly the headaches if those were nonspecific. It is most likely a coexisting diagnosis, though malignancy can sometimes coexist with immune dysregulation. It is not the primary mechanism of hypoglycemia here, because the hypoglycemia pattern is clearly insulin-antibody mediated rather than IGF-2 mediated.

Most important next management move

Now that IAS is confirmed:
- Remove potential triggers permanently, especially triamterene–hydrochlorothiazide
- Continue frequent low-glycemic meals
- Continue short-term glucose support as needed
- Because octreotide stabilized her glucose, it is reasonable as a bridge, but the more standard disease-modifying treatment for significant IAS is:
- glucocorticoids if hypoglycemia remains severe or recurrent
- Follow serial:
- bedside glucoses
- insulin antibody titers if available
- need for dextrose support

For the breast cancer:
- proceed with formal staging and receptor profiling and involve oncology/surgery in an age- and goals-of-care–appropriate plan.

Teaching pearl

When severe hypoglycemia shows high insulin, non-suppressed C-peptide, negative sulfonylurea testing, and negative pancreatic imaging, check insulin autoantibodies—postprandial timing is a major clue to Insulin Autoimmune Syndrome.

Round 8

User: The patient was started on a diet of frequent, small, low-carbohydrate meals and treatment with prednisone at a dose of 60 mg daily. A mastectomy with sentinel-lymph-node biopsy confirmed invasive ductal carcinoma with no neuroendocrine features. Over the following weeks, the glucose infusion and octreotide were discontinued, and the prednisone dose was slowly tapered. At a follow-up visit more than one year after discharge, the patient had no further episodes of severe hypoglycemia, although the insulin antibody titer remained strongly positive.

Resident:

Resident:
Hello, Chief Resident here.

This case concludes with the successful management of a complex dual diagnosis in an 85-year-old patient. The clinical course confirms the classic behavior of Insulin Autoimmune Syndrome (IAS) and highlights the importance of a systematic approach to hypoglycemia.

Final Case Synthesis:

  1. Diagnosis Confirmed: The patient had Insulin Autoimmune Syndrome (Hirata Disease), likely triggered by hydrochlorothiazide or potentially associated with the immune dysregulation of her concurrent invasive ductal carcinoma.
  2. Biochemical Signature: The "critical sample" (Glucose 16.2, Insulin 182, C-peptide 2.0) was the diagnostic pivot. The disproportionately high insulin relative to C-peptide (molar ratio >1) is the hallmark of antibody-bound insulin interference in the assay.
  3. Management Success: The combination of prednisone (to reduce antibody affinity and production) and a low-glycemic-index diet (to prevent the postprandial "loading" of the antibody reservoir) successfully stabilized her.
  4. Malignancy: The breast cancer was an independent but significant finding that explained her constitutional symptoms (weight loss). The lack of neuroendocrine features on pathology confirms it was not the source of ectopic insulin.

Final Probability-Based Diagnoses:

Key Takeaways and Teaching Pearls:

The patient's recovery and one-year stability demonstrate the effectiveness of removing the trigger and using targeted immunosuppression. This case serves as a reminder that in the elderly, multiple significant pathologies (autoimmune and neoplastic) can present simultaneously.

Attending:

Hello Attending Consultant here.

Critique of resident synthesis:

Refined 6-point recommendations:

  1. Calculate and document molar insulin:C-peptide ratio on all critical samples to confirm IAS biochemical signature.
  2. Discontinue all potential drug triggers (especially sulfonamide/thiazide agents) and re-evaluate for occult infection or other autoimmunity before long-term steroids.
  3. Taper prednisone rapidly (target <10 mg by 4–6 weeks) guided by clinical stability rather than IAA titer, as antibodies frequently persist >12 months.
  4. Stage and treat breast carcinoma independently per NCCN guidelines for age 85, incorporating goals-of-care discussion; tumor resection likely contributed to IAS remission.
  5. Maintain lifelong low-glycemic frequent feeding education and home glucose monitoring for first 6 months post-remission.
  6. Schedule multidisciplinary endocrine-oncology-geriatrics follow-up at 3, 6, and 12 months to monitor for IAS relapse, steroid sequelae, and cancer recurrence.

Expert:

Hello, Expert Clinician here.

Final unifying diagnosis

Insulin Autoimmune Syndrome (IAS, Hirata disease) causing recurrent severe endogenous hyperinsulinemic hypoglycemia, with concurrent invasive ductal breast carcinoma as a separate coexisting illness.

Why this is the best diagnosis

This is now fully established by:
- Whipple’s triad
- recurrent profound hypoglycemia
- markedly elevated insulin during hypoglycemia
- inappropriately non-suppressed C-peptide
- negative sulfonylurea screen
- negative pancreatic CT/MRI/EUS
- strongly positive insulin autoantibodies
- clinical response to dietary carbohydrate restriction, glucocorticoids, and temporary octreotide

The breast cancer was evaluated appropriately and had no neuroendocrine features, which argues against it being the source of ectopic insulin secretion.

Top differentials and why they no longer fit

  1. Insulinoma
    - Initially very plausible.
    - Became unlikely after negative high-quality pancreatic imaging and then was functionally displaced by the positive insulin antibody test.

  2. Sulfonylurea-induced hypoglycemia
    - Excluded by testing.

  3. Non-islet cell tumor hypoglycemia
    - Does not fit the biochemical profile because insulin would typically be suppressed.

  4. Adrenal insufficiency
    - Excluded with an adequate corticotropin stimulation response.

Key pivot in the case

The key pivot was the critical sample during severe hypoglycemia, followed by the positive insulin antibody titer. That combination transformed a broad hypoglycemia differential into a specific diagnosis of IAS.

What is especially important in this outcome

Two clinically important lessons emerge:

Most important management move, in retrospect

The most important successful management steps were:
- frequent, small, low-carbohydrate meals
- prednisone for severe/refractory IAS
- tapering off dextrose and octreotide once glucose stabilized
- removal of potential medication triggers
- definitive management of the breast cancer

Ongoing management priorities

Even though she is clinically well more than a year later, the priorities are:
- continued avoidance of possible trigger drugs
- education about recurrence symptoms
- periodic glucose monitoring if symptoms recur
- routine oncologic follow-up for breast cancer
- monitoring for steroid sequelae if any residual exposure-related issues remain

Teaching pearl

In IAS, treat the patient, not the antibody titer: hypoglycemia may resolve completely even while insulin autoantibodies remain strongly positive for months or years.

Top 15 Takeaways for Clinicians

  1. Whipple's triad converts a broad syncope differential into a focused hypoglycemia workup. Symptoms plus low glucose plus resolution with dextrose shifts the question from "Why did she faint?" to "Why is she hypoglycemic?"
  2. The "critical sample" during hypoglycemia is the single most important diagnostic step. Draw glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and sulfonylurea screen before dextrose.
  3. Postprandial hypoglycemia in a non-diabetic favors IAS or NIPHS over insulinoma. Insulinomas classically cause fasting hypoglycemia; consistently meal-related episodes redirect suspicion.
  4. Sulfhydryl-containing drugs can trigger Insulin Autoimmune Syndrome. Thiazide diuretics, methimazole, captopril, and alpha-lipoic acid are recognized triggers—discontinue immediately.
  5. Extremely high insulin with only moderately elevated C-peptide is the biochemical signature of IAS. Insulin autoantibodies prolong insulin half-life; calculate the molar insulin-to-C-peptide ratio.
  6. Negative high-quality pancreatic imaging with confirmed endogenous hyperinsulinism mandates insulin autoantibody testing. When CT, MRI, and EUS fail to localize a tumor, IAS becomes the leading diagnosis.
  7. Sulfonylurea screen is mandatory in every hypoglycemia workup. Surreptitious sulfonylurea ingestion exactly mimics endogenous hyperinsulinism.
  8. Treat the patient, not the antibody titer. IAS can remit clinically while insulin autoantibodies remain strongly positive for years.
  9. Prednisone is first-line disease-modifying therapy for severe IAS. Start at 0.5–1 mg/kg/day and taper slowly guided by clinical response.
  10. Frequent, small, low-glycemic-index meals are a cornerstone of IAS management. Reducing the postprandial insulin surge prevents "loading" of the antibody reservoir.
  11. Weight loss in a hypoglycemic patient must trigger a search for concurrent malignancy. Constitutional symptoms led to discovery of invasive ductal breast carcinoma as a parallel diagnosis.
  12. A normal cosyntropin stimulation test definitively excludes adrenal insufficiency. A peak cortisol >18 µg/dL after ACTH stimulation rules it out.
  13. Refractory hypoglycemia despite adequate oral intake and continuous dextrose signals a pathologic glucose-lowering process. Capture a critical sample before reflexively escalating dextrose.
  14. NICTH is distinguished from IAS by suppressed insulin and C-peptide. A patient with hypoglycemia plus high insulin/C-peptide does not have NICTH, regardless of concurrent malignancy.
  15. Recent migration history and thorough medication review are essential clinical clues in unexplained hypoglycemia. Eritrean origin and a hydrochlorothiazide prescription elevated IAS from obscure possibility to leading diagnosis.